Compare EVTL & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | RIGL |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.9M | 537.6M |
| IPO Year | N/A | 2000 |
| Metric | EVTL | RIGL |
|---|---|---|
| Price | $5.08 | $42.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $13.20 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 2.5M | 555.1K |
| Earning Date | 08-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | N/A | ★ $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | N/A | $0.22 |
| P/E Ratio | ★ N/A | $6.77 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $2.76 | $14.63 |
| 52 Week High | $15.99 | $52.24 |
| Indicator | EVTL | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 49.51 |
| Support Level | $5.60 | $40.52 |
| Resistance Level | $6.19 | $43.58 |
| Average True Range (ATR) | 0.64 | 2.88 |
| MACD | -0.05 | -1.04 |
| Stochastic Oscillator | 27.11 | 19.54 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero operating emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.